Literature DB >> 12861739

Brachytherapy for prostate cancer: the patient's perspective.

Peggy Ward-Smith1.   

Abstract

Prostate cancer is the most common malignancy, and the second most common cause of cancer among men in the United States. The treatment of localized prostate cancer is highly controversial, with many treatment options. Brachytherapy is the permanent implantation of radioisotopes directly into the tumor. Impotence, urinary and bowel dysfunction, as well as disease progression have frequently been utilized as disease-specific measurements of quality of life (QoL) among those with localized prostate cancer. The purpose of this qualitative study was to explore the impact brachytherapy has on QoL from the patient's perspective. Themes emerged from the data that surrounded the physical changes attributed to the treatment, treatment choices, knowledge of the disease, receiving the diagnosis, and use of medications to control symptoms post treatment. The findings from this study can be used for patient education and to assist patients in making appropriate treatment choices.

Entities:  

Mesh:

Year:  2003        PMID: 12861739

Source DB:  PubMed          Journal:  Urol Nurs        ISSN: 1053-816X


  3 in total

1.  Clinical practice guidelines of the French Association for Supportive Care in Cancer and the French Society for Psycho-oncology: refusal of treatment by adults afflicted with cancer.

Authors:  J C Faivre; V Adam; V Block; M Metzger; J Salleron; S Dauchy
Journal:  Support Care Cancer       Date:  2017-06-08       Impact factor: 3.603

2.  Disclosure of diagnosis and treatment among early stage prostate cancer survivors.

Authors:  Trent Jackson; Kimberly Davis; Lisa Haisfield; David Dawson; John Lynch; James Regan; Arnold Kwart; Barlow Lynch; Kathryn Taylor
Journal:  Patient Educ Couns       Date:  2009-09-22

3.  Changes in functional status associated with radiation for prostate cancer in older veterans.

Authors:  Carling Ursem; L Grisell Diaz-Ramirez; John Boscardin; Sei Lee
Journal:  J Geriatr Oncol       Date:  2020-12-30       Impact factor: 3.929

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.